Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening
Maria Grazia Lazzaroni(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Alexandra Balbir‐Gurman(Technion – Israel Institute of Technology), É. Hachulla(Centre Hospitalier Universitaire de Lille), Vanessa Smith(Ghent University Hospital), Rucsandra Dobrota(University of Zurich), Roger Hesselstrand(Lund University), Cecília Varjú(Université Paris Cité), Paolo Airó(University of Lisbon), Paola Caramaschi(University of Verona), Yannick Allanore(Inserm), Ilaria Cavazzana(Université Paris Cité), Valeria Riccieri(Sapienza University of Rome), Oliver Distler(University Hospital of Zurich), Katarzyna Romanowska‐Próchnicka(Medical University of Lodz), Emmanuel Chatelus(Laboratoire National de Référence), Enrico Colombo(Université Paris Cité), Gabriella Nagy(Université Paris Cité), Ana Carolina Araújo(Université Paris Cité)
Cited by 127
Related Papers
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
|New England Journal of Medicine|2009|857
Mapping and predicting mortality from systemic sclerosis
|Annals of the Rheumatic Diseases|2017|699
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432